Table of Contents
Overview
New York, NY – Aug 17, 2025 – Global Eliquis (Apixaban) Market size is forecasted to be valued at US$ 31.5 Billion by 2034 from US$ 20.1 Billion in 2024, growing at a CAGR of 4.6% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 34.1% share with a revenue of US$ 6.9 Billion.
Eliquis® (apixaban) is an oral, selective factor Xa inhibitor, developed to address the prevention and treatment of blood clot–related conditions. Approved for multiple indications, Eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of their recurrence.
Eliquis works by inhibiting factor Xa, a key enzyme in the coagulation cascade, thereby decreasing thrombin generation and clot formation. This targeted mechanism of action allows for effective anticoagulation with a predictable pharmacokinetic profile, reducing the need for routine coagulation monitoring.
Clinical trials, including the ARISTOTLE and AMPLIFY studies, have demonstrated that Eliquis provides significant reductions in stroke risk, major bleeding, and recurrent thromboembolic events compared to standard therapies. Its favorable safety profile and twice-daily oral administration make it a preferred choice for long-term anticoagulation in appropriate patient populations.
Eliquis is co-developed by Bristol Myers Squibb and Pfizer, reflecting a strategic collaboration to enhance patient outcomes in cardiovascular care. As a leading therapy in its class, Eliquis continues to expand access globally, improving quality of life for patients at risk of life-threatening clot-related events.
Key Takeaways
- In 2024, the Eliquis (Apixaban) market generated revenue of US$ 20.1 billion, with a declining CAGR of 4.6%, and is projected to reach US$ 31.5 billion by 2034.
- Atrial Fibrillation (AF) was the leading indication segment, accounting for 58.9% of the market share in 2024.
- The tablet dosage form held the largest share at 76.7% in 2024.
- By route of administration, the oral segment dominated with 87.1% market share in 2024.
- Within the distribution channel, retail pharmacies accounted for the largest share at 54.8% in 2024.
- North America represented the largest regional market, capturing 34.1% share in 2024.
Segmentation Analysis
- Indication Analysis: In 2024, Atrial Fibrillation (AF) accounted for 58.9% of the Eliquis market share. AF is prevalent, with a lifetime risk affecting one in three to five individuals over age 45, and incidence is rising due to aging populations and increasing risk factors like hypertension, diabetes, and obesity. This growing burden has significantly driven demand for effective anticoagulants such as apixaban, which provides stroke and systemic embolism prevention, making it the preferred therapeutic option in AF management.
- Form Analysis: Tablets held 76.7% of the Eliquis market in 2024, favored for their convenience, effectiveness, and high patient adherence. Apixaban tablets offer a fixed-dose regimen, unlike warfarin, which requires frequent monitoring. They are primarily prescribed for AF to prevent stroke and systemic embolism. Available in 2.5 mg (yellow, round) and 5 mg (pink, oval) film-coated variants, tablets are preferred by both patients and physicians for their ease of administration and reduced monitoring requirements.
- Route of Administration Analysis: Oral administration accounted for 87.1% of the Eliquis market in 2024, driven by its ease of use, efficacy, and favorable safety profile. Oral apixaban requires fewer dietary restrictions and has minimal food or drug interactions compared to warfarin. It is preferred over injectable anticoagulants, offering better patient comfort and adherence. Tablets can be swallowed whole or crushed for easier consumption, with dosing guidelines available for adults and pediatric patients weighing at least 35 kg.
- Distribution Channel Analysis: Retail pharmacies captured 54.8% of the Eliquis distribution channel share in 2024, supporting long-term thromboembolic disorder management. Their accessibility ensures patients can conveniently obtain medications, promoting adherence to anticoagulation therapy. Pharmacists provide essential counseling on administration, potential side effects, and drug interactions. With extensive reach across urban and rural areas, retail pharmacies ensure timely availability of apixaban, reducing the need for hospital visits and enhancing patient support through continuous guidance and monitoring.
Market Segments
By Indication
- Atrial Fibrillation (AF)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Post-Operative Venous Thromboembolism (VTE) Prophylaxis
- Others
By Form
- Tablet
- Capsule
By Route of Administration
- Oral
- Nasogastric (NG) Tube
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis
North America, led by the United States, remains the largest market for apixaban, supported by a high prevalence of cardiovascular conditions such as atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE). According to the CDC, venous thromboembolism (VTE) affects up to 900,000 Americans annually, with 60,000–100,000 deaths each year and many patients experiencing long-term complications. The aging population is expected to further increase the incidence of these disorders, sustaining demand for effective anticoagulants. The region benefits from advanced healthcare infrastructure, a well-developed pharmaceutical distribution network, and comprehensive insurance coverage, facilitating accessibility and adherence to apixaban therapy.
The Asia Pacific (APAC) region is projected to record the highest CAGR during the forecast period, driven by rising rates of cardiovascular diseases in China, India, Japan, and South Korea. Aging demographics, urbanization, and lifestyle changes are major contributors to disease growth. While initial adoption of direct oral anticoagulants (DOACs) was slower in APAC, increasing awareness among physicians and patients is accelerating market penetration. In India, generic versions such as Apigat and Bd-Pixa are widely available through suppliers like Aark Pharmaceuticals. Additionally, Zydus Lifesciences received U.S. FDA approval in March 2023 to market generic apixaban, manufactured in Ahmedabad, enhancing global and regional supply availability.
Emerging Trends
- Expanded Use in Pediatric Venous Thromboembolism (VTE): In April 2025, the U.S. FDA approved Eliquis for pediatric VTE treatment and recurrence prevention from birth onward, following at least five days of initial anticoagulation, expanding its clinical applicability to younger populations.
- Launch of Direct-to-Patient Access Program: Starting September 8, 2025, eligible U.S. patients can purchase Eliquis directly via the “Eliquis 360 Support” program, accessing prices over 40% lower than list, with nationwide delivery, improving affordability and patient access.
- Rising Prescription Trends and Market Growth: Global adoption of Eliquis continues to grow, driven by a superior safety profile, predictable pharmacokinetics, and simplified dosing compared to warfarin, resulting in improved patient adherence and favorable clinical outcomes across multiple healthcare markets.
- Shift in Cost Dynamics Driven by Generics and Policy: Apixaban’s pricing is under downward pressure from generics and policy reforms, including Australia’s adoption as the most prescribed oral anticoagulant and U.S. Medicare’s negotiated 2026 price cut of 56% versus 2023.
- Real-World Comparative and Clinical Studies: A VA–FDA collaboration launching spring 2025 will compare apixaban and rivaroxaban in nonvalvular atrial fibrillation among veterans, providing real-world evidence to guide anticoagulant choice based on safety, efficacy, and long-term patient outcomes.
Use Cases
- Stroke and Systemic Embolism Prevention in NVAF: Eliquis reduces the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation, offering a preferred alternative to warfarin due to lower bleeding risk and consistent anticoagulant effect.
- Prophylaxis of Deep Vein Thrombosis (DVT) Following Orthopedic Surgery: Indicated for preventing DVT and associated pulmonary embolism in adults undergoing hip or knee replacement surgery, Eliquis supports faster recovery by reducing clot-related postoperative complications.
- Treatment and Recurrence Risk Reduction in VTE: Used for treating DVT and pulmonary embolism in adults, Eliquis also reduces the risk of recurrence after initial therapy, offering both acute and long-term management benefits.
- VTE Treatment and Prevention in Pediatric Patients: Newly approved for pediatric VTE, Eliquis addresses treatment and recurrence prevention from birth onward after initial anticoagulation, filling a critical gap in pediatric anticoagulant therapy.
- Emergency and Surgical Management (Hemoadsorption): In urgent cardiac surgery, hemoadsorption with Cytosorb can reduce Eliquis blood concentration, lowering bleeding risk and enabling safer operative interventions in patients requiring rapid anticoagulant reversal.
Conclusion
Eliquis® (apixaban) has established itself as a leading oral anticoagulant due to its selective factor Xa inhibition, predictable pharmacokinetics, and favorable safety profile. In 2024, it generated US$ 20.1 billion in revenue, with atrial fibrillation as the largest indication segment and tablets as the dominant form.
North America led the market, while Asia Pacific showed the highest growth potential. Expanding clinical indications, such as pediatric VTE, and initiatives like direct-to-patient programs are enhancing accessibility. Despite pricing pressures from generics and policy changes, Eliquis is expected to reach US$ 31.5 billion by 2034, supported by sustained global adoption and clinical efficacy.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
